Compass Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Compass Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, with a record date of April 15, 2026.
NASDAQ
Compass Therapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
Compass Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to elect directors and ratify the appointment of its independent accounting firm.
NASDAQ
Compass Therapeutics announces the resignation of Vered Bisker-Leib as CEO and the appointment of Thomas Schuetz as the new CEO, effective May 28, 2024.
NASDAQ
Compass Therapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
DEF 14A: Compass Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals
Compass Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to elect directors and ratify the appointment of its independent accounting firm.